On March 16, Cingulate Inc received approval from the US Patent and Trademark Office (USPTO) for a key patent application related to its ADHD treatment. The patent protects the proprietary technology behind CTx-1301, the company's lead ADHD drug candidate. Following this announcement, Cingulate Inc (CING) shares surged in Monday morning trading.
